These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 34429006)
1. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Rizzo A; Ricci AD Expert Opin Investig Drugs; 2022 Apr; 31(4):415-423. PubMed ID: 34429006 [TBL] [Abstract][Full Text] [Related]
2. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533 [TBL] [Abstract][Full Text] [Related]
3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
4. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Rizzo A; Brandi G Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Lin ZF; Qin LX; Chen JH Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Rizzo A; Ricci AD Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275 [TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G Front Oncol; 2021; 11():803133. PubMed ID: 34976841 [TBL] [Abstract][Full Text] [Related]
8. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer? Dong A; Zhao Y; Li Z; Hu H J Gene Med; 2021 Feb; 23(2):e3294. PubMed ID: 33171529 [TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
12. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. Rizzo A; Mollica V; Massari F Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645 [TBL] [Abstract][Full Text] [Related]
13. Promising predictors of checkpoint inhibitor response in NSCLC. Alex F; Alfredo A Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120 [TBL] [Abstract][Full Text] [Related]
14. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K Front Immunol; 2021; 12():646874. PubMed ID: 33927719 [TBL] [Abstract][Full Text] [Related]
15. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047 [TBL] [Abstract][Full Text] [Related]
16. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Rizzo A; Ricci AD; Brandi G Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621 [TBL] [Abstract][Full Text] [Related]
17. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985 [TBL] [Abstract][Full Text] [Related]